The Animal Model Core (AMC) provides relevant experimental tools and animal models that would support and enhance the research approaches of CURE: DDRCC member in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), obesity and Parkinson diseases-related Gl dysmotility using mice as a prominent experimental model.-This is achieved through the following services i. Education and training of members on methods, protocols, best practice of animal use, and preparation of animal experimental protocols for institutional approval; ii. Access to well characterized relevant chemical genetic or experimental models of stress, IBS, colitis, visceral obesity and Parkinson disease-related constipation in rats or mice; iii Access to state-of-the art equipment use and training for functional bioassays to assess gastrointestinal propulsive motor function, visceral pain, intestinal permeability and inflammation, food intake microstructure, body composition, energy homeostasis and brain-gut interaction in mice or rats. iv. Performance of drug delivery, collection of body fluid and surgical procedures; v. Access to genetically modified mice via institutional shared resources. The vast array of animal models and methodological approaches offered is made possible through the complementary and well established expertise of the AMC Directors and Personnel in the fields of stress, brain-gut interactions, gut motility, visceral pain, intestinal inflammation and feeding behavior. In particular expertise of AMC Directors lead to substantial methodological advances namely the developed novel noninvasive monitoring of gut motility and visceral pain in conscious mice and acquisition of state-of-the the art equipment (EchoMRI, BIODAQ, metabolic cages and Ussing chambers) during the last granting period. These AMC services are essential not only for the success of the CURE:DDRCC members who are federally funded and anticipate to use the Core (33 members), but are also critical to spur new projects, including the 5 newly federally funded grants on energy metabolism that made use of the new Core equipment and expertise..

Public Health Relevance

The Animal Model Core plays a fundamental role to advance knowledge on several diseases including irritable bowel syndrome, inflammatory bowel diseases, constipation association with neurodegenerative disease and the interaction between the gut and the brain as it relates to food intake and metabolism. The unraveling of new mechanisms and testing new intervention using preclinical models will help to understand these disorders and advance therapeutic venues.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK041301-29
Application #
9392151
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
29
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bonfiglio, Ferdinando; Zheng, Tenghao; Garcia-Etxebarria, Koldo et al. (2018) Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology 155:168-179
Hoffman, Jill M; Sideri, Aristea; Ruiz, Jonathan J et al. (2018) Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis. Cell Mol Gastroenterol Hepatol 6:1-16
Kageyama, Shoichi; Nakamura, Kojiro; Fujii, Takehiro et al. (2018) Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside. Hepatology 68:258-273
Wen, Yi; Scott, David R; Vagin, Olga et al. (2018) Measurement of Internal pH in Helicobacter pylori by Using Green Fluorescent Protein Fluorimetry. J Bacteriol 200:
Koon, Hon Wai; Wang, Jiani; Mussatto, Caroline C et al. (2018) Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-?B Activity. Antimicrob Agents Chemother 62:
Wang, Jiani; Ghali, Sally; Xu, Chunlan et al. (2018) Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Gastroenterology 154:1737-1750
Manatsathit, Wuttiporn; Khrucharoen, Usah; Jensen, Dennis M et al. (2018) Laparotomy and intraoperative enteroscopy for obscure gastrointestinal bleeding before and after the era of video capsule endoscopy and deep enteroscopy: A tertiary center experience. Am J Surg 215:603-609
Rankin, Carl Robert; Theodorou, Evangelos; Man Law, Ivy Ka et al. (2018) Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 315:G722-G733
Park, S H; Naliboff, B D; Shih, W et al. (2018) Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterol Motil 30:
Dong, Tien; Pisegna, Joseph (2018) Passing the ""Acid Test"": Do Proton Pump Inhibitors Affect the Composition of the Microbiome? Dig Dis Sci :

Showing the most recent 10 out of 1097 publications